MAPT and Alzheimer disease: For example, the success of the donanemab TRAILBLAZER‐ALZ2 study has been accredited to their participant stratification‐based tau burden, selecting specifically those early AD patients that were Aβ positive (CL > 37) and had intermediate tau PET burden.8